Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | WNT3A | P56704 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20508020 | 0.90 | WNT3A (0.49) | RAB9AKMT2ASMN1; SMN2MAPK1WNT3A | |
| SCHEMBL20507940 | 0.90 | WNT3A (0.57) | RAB9AKMT2ASMN1; SMN2MAPK1WNT3A | |
| SCHEMBL20507899 | 0.87 | WNT3A (0.48) | RAB9AKMT2ASMN1; SMN2MAPK1WNT3A | |
| SCHEMBL20507964 | 0.86 | WNT3A (0.47) | RAB9AKMT2ASMN1; SMN2MAPK1WNT3A | |
| SCHEMBL20508039 | 0.86 | SCD (0.47) | RAB9AKMT2ASMN1; SMN2WNT3ANPC1 | |
| SCHEMBL20508213 | 0.86 | WNT3A (0.56) | RAB9AKMT2ASMN1; SMN2WNT3ANPC1 | |
| SCHEMBL20508211 | 0.85 | WNT3A (0.52) | RAB9AWNT3ANPC1HPGD | |
| SCHEMBL23699256 | 0.84 | WNT3A (0.53) | SMN1; SMN2WNT3ATP53POLB | |
| SCHEMBL20508095 | 0.83 | WNT3A (0.52) | MAPK1WNT3A | |
| SCHEMBL20508144 | 0.82 | WNT3A (0.52) | MAPK1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388428-B1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) | 2021-08-04 | — | — | EP | claimed |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-03 | — | — | US | claimed |
| EP-3388428-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | Suzhou Sinovent Pharmaceuticals Company (CN) | 2018-10-17 | — | — | EP | claimed |
| US-20180271846-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2018-09-27 | — | — | US | claimed |
| EP-3388428-B1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) | 2021-08-04 | — | — | EP | disclosed |
| EP-3388428-B1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | SUZHOU SINOVENT PHARMACEUTICALS COMPANY (CN) | 2021-08-04 | — | — | EP | disclosed |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-03 | — | — | US | disclosed |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2020-11-03 | — | — | US | disclosed |
| EP-3388428-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | Suzhou Sinovent Pharmaceuticals Company (CN) | 2018-10-17 | — | — | EP | disclosed |
| US-20180271846-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | Suzhou Sinovent Pharmaceuticals Co., Ltd. (CN) | 2018-09-27 | — | — | US | disclosed |
| WO-2017097216-A9 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | 杭州雷索药业有限公司 | 2017-11-23 | — | — | WO | disclosed |
| WO-2017097216-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | 杭州雷索药业有限公司 | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180271846-A1 | FIVE-MEMBERED HETEROCYCLIC AMIDES WNT PATHWAY INHIBITOR | WNT1, WNT3, WNT3A | RAB9A 810/4885KMT2A 2624/4885SMN1; SMN2 4801/4885 |
| US-10821104-B2 | Five-membered heterocyclic amides WNT pathway inhibitor | WNT1, WNT3, WNT3A | RAB9A 613/4885KMT2A 2800/4885SMN1; SMN2 4735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.